When the MSSMs are compared with the HMECs, several genes display differential expression in a mode consistent with previous publications, where they have been shown to be significant for malignant progression or metastasis: down-regulation of the tumour suppressor and inhibitor of mitotic phase entry 14-3-3σ (SFN) [16,17], the serine protease inhibitor SPINT2 [18] and JUP (γ-catenin) [19]; and up-regulation of FES [20] and SPARC [21]. The gene discussed is SPARC; the disease is neoplasm.